Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness

Published:December 04, 2021DOI:


      Introduction: The aim of this analysis is to assess the pharmacological costs of trifluridine/tipiracil as first-line treatment in metastatic colorectal cancer (mCRC) patients who were not candidates for combination with cytotoxic chemotherapies.
      Discussion: TASCO1 Trial was considered (153 patients). Differences in costs between the 2 arms (trifluridine/tipiracil plus bevacizumab vs. capecitabine plus bevacizumab) was 9113 € (10 264 USD), with a cost savings of 1982 € (2232 USD) per month of overall survival (OS)-gain.
      Conclusion: Trifluridine/tipiracil could be consider a cost-effective treatment also in first-line for mCRC patients who were not candidates for combination with cytotoxic chemotherapies.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mayer RJ
        • Van Cutsem E
        • Falcone A
        • et al.
        Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
        N Engl J Med. 2015; 372: 1909-1919
        • Giuliani J
        • Bonetti A
        Regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer? a perspective on the basis of pharmacological costs.
        Clin Colorectal Cancer. 2018; 17: e381-e383
        • Giuliani J
        • Bonetti A
        Economic sustainability of trifluridine/tipiracil for the treatment of refractory metastatic colorectal cancer in real life.
        Clin Colorectal Cancer. 2020; 19: 181-182
        • Van Cutsem E
        • Danielewicz I
        • Saunders MP
        • et al.
        Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study.
        Ann Oncol. 2020; 31: 1160-1168
        • Van Cutsem E
        • Danielewicz I
        • Marc P
        • et al.
        Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): results of the final analysis on the overall survival.
        J Clin Oncol. 2021; 39: 14
        • Giuliani J
        • Bonetti A
        The economic impact of biosimilars in oncology and hematology: the case of trastuzumab and rituximab.
        Anticancer Res. 2019; 39: 3971-3973
        • Cherny NI
        • Sullivan R
        • Dafni U
        • et al.
        A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).
        Ann Oncol. 2015; 26: 1547-1573
        • Giuliani J
        • Bonetti A
        Which grade is of clinical benefit in the randomised controlled trials? The example of 54th American Society of Clinical Oncology annual meeting, 2018.
        Eur J Cancer. 2018; 104: 233-235
        • Hofmarcher T
        • Lindgren P
        • Wilking N
        • Jönsson B
        The cost of cancer in Europe 2018.
        Eur J Cancer. 2020; 129: 41-49
        • Azimi NA
        • Welch HG
        The effectiveness of cost-effectiveness analysis in containing costs.
        J Gen Intern Med. 1998; 13: 664
        • Giuliani J
        • Bonetti A
        Financial toxicity and non-small cell lung cancer treatment: the optimization in the choice of immune check point inhibitors.
        Anticancer Res. 2019; 39: 3961-3965
        • Giuliani J
        • Bonetti A
        Immunotherapy in first-line for advanced non-small cell lung cancer:a cost-effective choice?.
        Recenti Prog Med. 2019; 110: 138-143
        • Giuliani J
        • Bonetti A
        Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) level.
        Oral Oncol. 2019; 97: 143-145
        • Giuliani J
        • Bonetti A
        Nivolumab in second-line treatment for advanced non-small-cell lung cancer with squamous-cell histology: a perspective based on pharmacologic costs.
        Clin Lung Cancer. 2017; 18: e363-e365
        • Giuliani J
        • Bonetti A
        Nivolumab is a cost-effective second-line treatment for metastatic renal-cell carcinoma.
        Clin Genitourin Cancer. 2018; 16: e557-e562